Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of fosmanogepix for invasive mold infections in adults
NL-OMON60923Phase 3Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Apr 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fosmanogepix in Invasive Mold Infections (IMIs), aspergillosis, fusariosis and 2 more, sponsored by Basilea Pharmaceutica. Primary endpoint: Day 42 all-cause mortality rate. Started Apr 2026; status: recruiting.
02
Drugs
fosmanogepix
03
Conditions
Invasive Mold Infections (IMIs)aspergillosisfusariosislomentosporiosismucormycosis
Beyond the preview
Go deeper on NL-OMON60923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60923.